Other News To Note
BioAlliance Pharma SA, of Paris, inked an exclusive license agreement for Sitavig (acyclovir Lauriad) with Abic Marketing Ltd., a subsidiary of Jerusalem-based Teva Pharmaceutical Industries Ltd. for commercialization rights in Israel. Sitavig, based on BioAlliance's mucoadhesive buccal technology, is in development for treating recurrent labial herpes in immunocompetent patients presenting more than four episodes per year.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST